Shattuck Labs, Inc. Proceeds from Warrant Exercises
Shattuck Labs, Inc. (STTK) reported Proceeds from Warrant Exercises of $52.78 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromWarrantExercises · last filed 2026-08-11
- Shattuck Labs, Inc. proceeds from warrant exercises for the quarter ending 2026-06-30 was $47.33M.
- Shattuck Labs, Inc. proceeds from warrant exercises for the quarter ending 2026-03-31 was $5.44M.
- Shattuck Labs, Inc. proceeds from warrant exercises for the quarter ending 2025-06-30 was $0.00.
- Shattuck Labs, Inc. proceeds from warrant exercises for the quarter ending 2025-03-31 was $0.00.
- Shattuck Labs, Inc. proceeds from warrant exercises for fiscal 2025 was $139.00K.
- Shattuck Labs, Inc. proceeds from warrant exercises for fiscal 2024 was $0.00.
| Period end | Proceeds from Warrant Exercises 3 month | Proceeds from Warrant Exercises 6 month | Proceeds from Warrant Exercises 12 month |
|---|---|---|---|
| 2026-06-30 | $47.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $52.78M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $5.44M 10-Q · filed 2026-05-07 | ||
| 2025-12-31 | $139.00K 10-K · filed 2026-03-05 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | ||
| 2024-12-31 | $0.00 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |